February 26, 2024Open Access

TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

View Full Paper

Ask AI

Bookmark

Abstract

All grade 3 or higher treatment-related AEs for subjects receiving at least one dose of combination therapy. Grade 2 treatment-related AES are included if >10% frequency

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bitting et al. (2024) studied this question.

synapsesocial.com/papers/68e779deb6db6435876ee18e https://doi.org/10.1158/2767-9764.25288976

View Full Paper

Ask AI

Bookmark

Abstract

All grade 3 or higher treatment-related AEs for subjects receiving at least one dose of combination therapy. Grade 2 treatment-related AES are included if >10% frequency

TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Abstract

Discussion

Cite This Study

TABLE 2 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Abstract

Discussion

Cite This Study

Keep reading

Keep reading